Terns Pharmaceuticals’ Oral GLP-1 Drug Demonstrates Promising Weight Loss Results

Terns Pharmaceuticals' TERN-601:
An experimental oral GLP-1 receptor agonist showed significant weight loss in a Phase 1 clinical trial. The highest dose resulted in a 5.5% reduction in body weight over 28 days, with 67% of participants achieving a weight loss of 5% or more.

Dose-Dependent Weight Loss:
The trial demonstrated dose-dependent weight loss, with the low-dose cohort achieving 11% and the middle dose achieving 33% weight loss of 5% or greater.

Safety and Tolerability:
The drug was generally well-tolerated, with adverse effects mainly being mild gastrointestinal events, consistent with the GLP-1 drug class.

Future Plans:
Terns Pharmaceuticals plans to advance TERN-601 into Phase 2 clinical trials in 2025, following feedback from scientific advisors and regulators.

Comparison with Other GLP-1 Drugs:
The results are comparable to other oral GLP-1 drugs in development, such as Structure Therapeutics' GSBR-1290 and Novo Nordisk's amycretin, which have shown similar weight loss percentages in early trials.